Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Long-read sequencing quantifies synthetic mRNA abundance, integrity and host response in vivo

Synthetic mRNA can be used to reprogram biological systems and is increasingly used in vaccines, gene therapies and other advanced therapeutics. However, measuring mRNA abundance, molecular integrity and biological effects in complex samples remains challenging. Existing assays typically quantify short transcript regions or infer delivery from lipid or protein readouts. Here we present a long-read nanopore sequencing method that directly quantifies synthetic mRNA in complex cell and tissue samples. The approach enables absolute quantification of full-length synthetic mRNA, maps degradation at nucleotide resolution and simultaneously profiles associated host transcriptional responses. Applied to lipid nanoparticle (LNP) delivered mRNA in mice, the method revealed tissue-specific delivery and degradation patterns and uncovered a critical disconnect between mRNA accumulation and protein expression across organs. This approach enables integrated measurement of mRNA fate, integrity and biological responses, and will enable mechanistic studies of RNA delivery, stability, translation and innate immune recognition.

Victoria McLeod, D. Yuen, Moore Z. Chen et al. · 0 citations
Review Open access Aug 2026

Beyond PEG: Emerging Polymer Lipid Alternatives for Lipid Nanoparticle (LNP) Formulations

ABSTRACT Lipid nanoparticles (LNPs) have rapidly emerged as the leading delivery platform for nucleic acid therapeutics due to their high encapsulation efficiency, scalable manufacturing, and clinical success in siRNA and mRNA medicines. Poly(ethylene glycol)‐lipids ((PEG)–lipids) have been central to this progress by providing steric stabilization, size control, and tunable biodistribution. However, PEGylation also introduces important limitations, including complement activation, pre‐existing and treatment‐induced anti‐PEG antibodies, and accelerated blood clearance, which increasingly constrain repeated and long‐term dosing strategies. This review focuses on recent advances in PEG‐alternative LNP designs, including non‐PEG polymers, zwitterionic and biomimetic lipids, polypeptides, and structurally modified PEG analogues. We compare how polymer chemistry, anchor geometry, and grafting architecture influence LNP formation, physicochemical properties, biodistribution, cellular uptake, and immunological outcomes. Moreover, we discuss key challenges that remain in translating PEG‐free and PEG‐modified LNPs toward clinical application and propose future directions to better understand in vivo behavior and enable rational design of next‐generation stealth LNPs. Overall, PEG lipid alternatives should not be viewed as simple PEG mimics, but as distinct surface‐engineering materials that create new nano‐bio interfaces and reshape LNP behavior in biological systems.

Zihnil A I Mazrad, Yi Ju, S. J. Kent et al. · 0 citations